2020 AGM PRESENTATION

DISCLAIMER

This presentation has been prepared by Resonance Health Limited only and may contain forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. In any forward looking statement in which Resonance Health Limited expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health Limited is not under any duty to update forward-looking statements unless required by law.

This presentation is not an offer of the sale of securities.

Resonance Health and their respective directors, employees, associates or agents:

a) make no representations or warranties, express or implied, in relation to this presentation or the accuracy, reliability or completeness of any information in it or the performance of Resonance Health; and
b) accepts no responsibility for the accuracy or completeness of this presentation and the information contained in it.

This presentation is intended to provide background information only and does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, not may it or any part of it form the basis of, or be relied on in any connection with any contract or commitment whatsoever. The information in this presentation does not take into account the objectives, financial situation or particular needs of any person. Nothing contained in this presentation constitutes investment, legal, tax or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries. Potential investors are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health Limited would desire or require in reaching an investment decision.

To the maximum extend possible by law, none of Resonance Health, their offices, directors, employees, associates or agents, not any other persons accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents of otherwise arising in connection with it or any error or omissions on it.

Our MISSION

To be a global leader developing **innovative** healthcare products and services, to work diligently to deliver the highest quality products for customers, and to operate with **integrity** and **excellence** in driving growth for shareholders.

- Resonance Health is an Australian technology company focused on the development and commercialisation of medical diagnostic and other products and services;
- Strong focus on expansion and growth through increased sales and diversification;
- Strong IP position, patents, provisional patents, and proprietary in-house IP;
- Internationally recognised as providing the gold standard in iron quantification, with regulatory cleared diagnostic software (FerriScan and FerriSmart) for the measurement of liver iron concentration;
- A radiology distribution network of over 50 countries, now also supplemented by strategic global channel partners.

CORPORATE SNAPSHOT

Financial Information (17 November 2020, AUD)

Share Price	**$0.165**
Number of Shares	444.3m
52 Week Range	$0.092 - $0.28
Top 20 Shareholders	50.04%
Board & Management	18.10%
Market Capitalisation	**$73.31m**
Cash as of 17 Nov 2020	$7.53m

Board & Management

Dr Martin Blake	- Non-executive Chairman
Mr Simon Panton	- Non-executive Director
Dr Travis Baroni	- Non-executive Director
Mr Mitchell Wells	- Non-executive Director
Ms Alison Laws	- Chief Executive Officer
Mr Agha Shahzad	- Chief Financial Officer & Company Secretary

Share Price Performance (5 years)

Cash Balance over Time



PERFORMANCE SNAPSHOT

- Reportable total revenue for FY 2020 was **$3.9 million;**
- NPAT: Excluding non-cash share-based payment expenses for employee and Director options, **the Company recorded a positive profit result of $1.1 million for the full year;**
- Cashflow positive from operating activities for **10 consecutive quarters** (since March 2018 quarter);
- **Expanded clinical trial workstream**: 9 active multi-year trials with NASDAQ-listed and European pharmaceutical and therapeutic companies. Total contract value remaining for current trials is approx. USD $3.78 million (~$5.1 million AUD), subject to successful completion of trials. Over the FY, additional Work Orders and amendments were executed for an approximate sum of USD$2.9m (~$4 million AUD), subject to successful completion of these trials.

Revenue Breakdown by funding source



Revenue Breakdown by product/service



DIVERSIFICATION THROUGH R&D

Research & Development pipeline has three key areas of focus;

1. **artificial intelligence (AI);**
2. **imaging**, and;
3. **molecular medicine.**

R&D:
ARTIFICIAL INTELLIGENCE

FerriSmart
Powered by FerriScan



At present, Over 330,000 affected infants are born annually (83% sickle cell disorders, 17% thalassaemias). Haemoglobin disorders account for about 3.4% of deaths in children less than 5 years of age[1].

Sickle cell is an inherited blood disorder that affects 1 to 3 million Americans and 8 to 10 percent of African Americans. It is estimated that there were more than 100 million sickle cell carriers worldwide[2].

- Automated system for measuring liver iron concentration (LIC);
- Can be fully integrated into existing radiology workflows, with patient results returned in real-time;
- Agreements signed this FY with Siemens Healthcare and 3DR Laboratories to extend distribution network. These agreements allow for FerriSmart to be offered instantly to existing customers of Siemens and 3DR;
- FerriSmart is a regulatory cleared (TGA, CE Mark, FDA) solution for the measurement of LIC, and FDA cleared MR companion diagnostic for use with deferasirox (a compound used to treat iron overload – an iron chelator);
- Delivered through Company's own secure web portal or via verified channel partners (Siemens, TeraRecon, 3DR, and Blackford).

HepaFat-AI
for automated measurement of liver fat

It is estimated that the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is between 24% and 30% of the global population [3], meaning that **between 1.8 and 2.3 billion people may currently have NAFLD.** Of these, it is estimated that 20%, or up to 468 million, will also develop non-alcoholic steatohepatitis (NASH). NASH is the most severe form of NAFLD where inflammation can cause liver damage and fibrosis.

If the prevalence of NAFLD continues to rise in line with the obesity epidemic, it is predicted that **the healthcare burden of NAFLD over the next 10 years could increase to $1.005 trillion in the United States, and €334 billion across Germany, France, Italy, and the United Kingdom[4]**.

- HepaFat-AI is an automated system for measuring a patient's volumetric liver fat fraction (liver fat) using MRI images that provides rapid, reproducible results;
- May be integrated into radiology workflows for faster pathways to established customer bases;
- Applying for regulatory clearances: Application submitted to US FDA, work commenced for TGA and CE Mark.

As of February 2017, Trialtrove reported that there were 594 trials for symptom relief and/or for the treatment, modification, or cure of NAFLD. Of these trials, one-third are industry sponsored trials (193), 47% of which are completed or terminated, while 37% are ongoing and 16% planned to initiate[5].



Note: three trials have initiated YTD since February 2017

Source: Trialtrove, February 2017

Due to the quality-controlled, standardised nature of HepaFat-AI, a patient may have a scan at any verified MRI centre, anywhere in the world, and receive accurate, reliable results. This makes HepaFat-AI ideally suited for use in multi-center clinical trials.

ALERT-PE

Pulmonary embolism (PE) is part of the venous thromboembolism (VTE) spectrum, which ranges from asymptomatic deep vein thrombosis (DVT) to fatal PE, and is a blockage of the pulmonary arteries in the lungs caused by blood clots[6].

PE is the third most common cause of death in hospitalised patients. Autopsy studies have shown that approximately 60% of patients who have died in hospital had PE, with the diagnosis having been missed in up to 70% of the cases[7].

It is estimated that there are 1 million cases of VTE and over 500,000 hospital admissions in the United States, with **annual costs exceeding an estimated 10 billion US dollars[8]**. With prompt treatment, medical intervention can be highly effective and it has been shown to greatly reduce the likelihood of death[9].

- Alert-PE is a tool for the automated review of chest tomography (CT) scans of patients with suspected PE that can rapidly triage time-sensitive chest scans for radiologists to flag cases of suspected positive PE;
- Neural network training has been performed using datasets of the lungs provided via the collaboration with Perth Radiological Clinic (PRC), one of Western Australia's largest radiology practices;
- A progress update is expected within the next 6 months.

CYSTIC FIBROSIS TOOL



Cystic Fibrosis (CF) is a serious progressive genetic disease found mainly in Caucasians that causes persistent lung infections and cumulative, progressive and irreversible lung damage that severely limits the quality and length of life of those living with the condition.

According to the US based Cystic Fibrosis Foundation, more than 70,000 people worldwide suffer from CF with approximately 1,000 new cases of CF being diagnosed each year in the US alone. In the USA it is estimated that 1 in 25 Caucasian people are carriers of one mutation of the CF gene[10]. At present there is no cure for CF, with many lives still being cut short by the disease due to persistent lung infections and loss of lung function[11].

- Licence agreement signed with Telethon Kids Institute and Erasmus University Medical Centre for the use of CT datasets that will be used in the potential development of a new AI solution for the automated assessment of lung disease progression in patients with CF;
- Resonance Health will aim to develop, and obtain regulatory clearance of, a new AI CF solution to standardise and automate the detection and quantification of lung disease in CF patients;
- The first datasets have been received and are currently being processed for machine learning;
- An update will be provided within the next 3-6 months on the AI model training progress.

EXPANSION VIA RADIOLOGY PLATFORMS

Resonance Health
Be Better Informed

CHANNEL PARTNERS

TERARECON

SIEMENS Healthineers

3DR LABS, LLC
An ACCUMEN® Company

Blackford

R&D:
IMAGING

PRODUCT IMPROVEMENTS

- **3T CALIBRATION:** Resonance Health is currently studying whether the FerriScan service can be calibrated to 3 Tesla (3T) scanners. If successful, this would also allow customers to select the FerriScan service on either 1.5 or 3T MRI machines.

- **SHORTER ACQUISITION:** Significant progress has been made in the Company's trials looking at several protocols attempting to significantly decrease the acquisition time for FerriScan for 1.5 and 3T scanners. A shorter acquisition time for the FerriScan service would considerably reduce the time spent by a patient inside an MRI machine whilst also lowering the total costs to customers.



LIVER FIBROSIS PROJECT

- **NOVEL METHOD FOR FIBROSIS ASSESSMENT:** The Company's study to investigate the ability of a novel non-invasive MRI method to assess liver fibrosis is progressing well. Recruitment is now 50% complete, with the first stage of the fibrosis project expected to be completed by early 2021.

"Liver biopsy remains the Gold Standard for the assessment of fibrosis, despite several alternative techniques being available. We are developing a non-invasive MRI-based method for the assessment of liver fibrosis without need for additional equipment and contrast agents, and are looking forward to work progressing."

Dr Wenjie Pang, Acting Chief Scientific Officer

R&D:
MOLECULAR MEDICINE



ANTIVIRAL THERAPIES PROJECT

While vaccination can prevent Hepatitis B, globally some **250 million people remain chronically infected, including an estimated 230,000 in Australia (of which 2 out 5 remain undiagnosed)**[12] . Up to 25% of people with Chronic Hepatitis B (CHB) die from cirrhosis, liver complications, or liver cancer (specifically, hepatocellular carcinoma)[13]. Given that current treatments are unable to completely eliminate the virus and patients require life long care, **there is an urgent unmet need to find better medicines**.

- Resonance Health is investigating the use of Antisense Oligonucleotides (ASOs) as a treatment for CHB infection; using a cell model of the liver, the Company's ASOs were shown to block the expression of a human protein critical to viral replication;
- A Provisional Patent was filed covering the application of novel ASOs to treat liver related disease;
- In addition to CHB, Resonance Health will develop academic collaborations to investigate the potential use of these ASOs for the treatment of HIV related viral hepatitis, for HCV (in cases of treatment failure) and in patients co-infected with 2 or more viruses;
- The antiviral efficacy of three (3) promising ASOs is undergoing in vitro testing by the Doherty Institute; and we are hopeful that the outcome of that work should be known in the first half of 2021.

LIVER IRON BLOOD TEST PROJECT

At present, a very common blood test (serum ferritin, 'SF') is routinely used as a proxy for the iron status of a patient. Although SF is routinely used, it is an acute phase reactant and can be **affected** by the presence of many other conditions such as inflammation, infections, cancer, and obesity. Additionally, **once SF reaches a saturation point the correlation between SF and total body iron stores breaks down.**

Whilst the use of FerriScan remains the global gold standard for quantifying LIC, the Company is actively pursuing alternative biochemical methods to better assist clinicians to diagnose and monitor iron overload in locations where access to MRI is limited.

- In an ongoing and unpublished study of 59 Vietnamese Thalassemia patients and control subjects who underwent MRI (FerriScan) for Liver Iron Concentration quantification, the Company reported that a combination of 3 newly identified blood biomarkers **performed better** than SF in predicting clinically relevant LIC thresholds;
- A Provisional patent was filed covering the discovery and use of these novel blood markers to determine an individual's iron status;
- A follow-up validation study was recently established to test the efficacy of these novel blood markers in a European cohort of Thalassemic and non-Thalassemic patients with iron overload.

MOLECULAR MEDICINE PROGRESS

"The application of nucleic acid technology and advanced disease marker identification is changing medicine on a daily basis. In developing ASO medicines and diagnostic tools to address the global challenges of liver disease, the efforts of the Molecular Medicine R&D group remain fully aligned with the Company's goal of advancing ground-breaking technologies to help patients across the globe."

Dr Sherif Boulos, R&D Manager, Molecular Medicine

Antiviral Therapies - Project



Liver Iron Blood Test - Project



References

1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008 Jun;86(6):480-487. DOI: 10.2471/blt.06.036673.
2. American Society of Hematology. (n.d.). Patients – Sickle Cell Disease. Retrieved from https://www.hematology.org/education/patients/anemia/sickle-cell-trait
3. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clinics in Liver Disease. 2016;20:205-214
4. Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016).
5. Trialtrove. (2017). First for Fatty Liver – Who will win the race to be the first NAFLD treatment to market?. Retrieved from https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/files/pdfs/whitepapers/nafld_whitepaper.pdf
6. Singer, A. J., Thode, H. C., Jr, & Peacock, W. F., 4th (2016). Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. Clinical and experimental emergency medicine, 3(3), 126–131. https://doi.org/10.15441/ceem.15.096
7. Ouellette, D. What percentage of hospitalized patients have pulmonary embolism (PE). https://www.medscape.com/answers/300901-8452/what-percentage-of-hospitalized-patients-havepulmonary-embolism-pe
8. Singer, A. J., Thode, H. C., Jr, & Peacock, W. F., 4th (2016). Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. Clinical and experimental emergency medicine, 3(3), 126–131. https://doi.org/10.15441/ceem.15.096
9. Mayo Clinic. Pulmonary embolism. https://www.mayoclinic.org/diseases-conditions/pulmonaryembolism/symptoms-causes/syc-20354647
10. Edwards QT, Seibert D, Macri C, Covington C, Tilghman J (November 2004). "Assessing ethnicity in preconception counseling: genetics--what nurse practitioners need to know". Journal of the American Academy of Nurse Practitioners. 16 (11): 472–80.
11. Cystic Fibrosis Foundation. (2018). About Cystic Fibrosis. Retrieved from https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/
12. Doherty institute. (2018). About Viral Hepatitis. Retrieved from https://www.doherty.edu.au/whoccvh/about-viral-hepatitis
13. ASHM. (2018). Prevalence and epidemiology of hepatitis B. Retrieved from https://www.hepatitisb.org.au/prevalence-andepidemiology-of-hepatitis-b/

VALUE PROPOSITION

Manufacturer of regulatory cleared medical devices (SaMD)

- 5 Regulatory Cleared Services
- Targeting FDA clearance on second AI solution, HepaFat-AI

Diverse R&D Pipeline

- Artificial Intelligence
- Imaging
- Molecular Medicine

Growing Revenue

- Services being used in 9 active clinical trials
- Increased revenue despite impact from COVID-19
- 4 channel partners for distribution of AI product

Strong Balance Sheet

- Cash balance of $7.5m
- Cash flow positive from the last 10 consecutive quarters
- Company has no debt